<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03787043</url>
  </required_header>
  <id_info>
    <org_study_id>MP_C102</org_study_id>
    <nct_id>NCT03787043</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of Food on Fixed-Dose Combination of MP-513 10 mg and Metformin XR 750 mg</brief_title>
  <official_title>A Randomized, Open-label, Single-dosing, 2X2 Crossover Study to Evaluate the Effect of Food on the Safety and Pharmacokinetics of Fixed-dose Combination of MP-513 10mg and Metformin XR 750mg in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Handok Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Handok Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and pharmacokinetic characteristics of
      fixed-dose combination of MP-513 10mg and metformin XR 750mg administered in a high fat fed
      state versus fasting state to healthy male volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Randomized, open-label, single-dosing, two-treatment, two-sequence, two-period,
           crossover design

        2. Wash-out period: 14 days from the first dosing

        3. Drug concentration analytical device: UPLC-MS/MS
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2014</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC of MP-513 and metformin</measure>
    <time_frame>0(pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hours post-dose for each period(a total of 36 times, with 18 times per period)</time_frame>
    <description>PK</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of MP-513 and metformin</measure>
    <time_frame>0(pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48, 72 hours post-dose for each period(a total of 36 times, with 18 times per period)</time_frame>
    <description>PK</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Sequence Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st period: FDC(MP-513 10mg/Metformin XR 750mg) under fasted
2nd period: FDC(MP-513 10mg/Metformin XR 750mg) under fed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st period: FDC(MP-513 10mg/Metformin XR 750mg) under fed
2nd period: FDC(MP-513 10mg/Metformin XR 750mg) under fasted</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FDC(MP-513 10mg/Metformin XR 750mg)</intervention_name>
    <arm_group_label>Sequence Group A</arm_group_label>
    <arm_group_label>Sequence Group B</arm_group_label>
    <other_name>HL1511</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A healthy male adult at the age of 20 to 45 (both inclusive) at the time of screening
             test.

          -  Body weight equal to or greater than 55 kg and calculated ideal body weight (IBW)
             within ±20%

          -  An individual who has been given and fully understood detailed explanations about this
             study, decides to participate in the study of his own will, and provides written
             informed consent to comply with instructions.

        Exclusion Criteria:

          -  History or presence of any clinically significant diseases in the hepatobiliary,
             renal, nervous(central or peripheral), respiratory, hemato-oncology, cardiovascular,
             urinary, musculoskeletal, immune, ear, nose and throat (ENT), mental, and,
             particularly, endocrine systems (e.g., diabetes mellitus, hyperlipidemia, etc.).

          -  History of any gastrointestinal disease that may affect absorption of the study drug
             (Crohn's disease, ulcer, acute or chronic pancreatitis, etc.) or gastrointestinal
             surgeries (except for simple appendectomy or hernia repair).

          -  Hypersensitivity to MP-513 or drugs containing metformin or other drugs in the same
             class as ingredients or to other drugs

          -  Vital signs in a sitting position corresponding to at least one of the following
             criteria: systolic blood pressure ≥ 140 mmHg or &lt; 90 mmHg, or diastolic blood pressure
             ≥ 95 mmHg or &lt; 60 mmHg.

          -  Serum creatine &gt; upper limit of reference range

          -  Required to refrain from food intake for at least 24 hours during the study period due
             to surgery or religious reason.

          -  History or presence of drug abuse.

          -  Administration of drugs that either induce or inhibit drug metabolizing enzymes, such
             as barbitals, within 1 month prior to the first dosing.

          -  Intake of food or beverage containing grapefruit or cranberry within 1 week prior to
             the first dosing.

          -  Administration of any ethical drugs or traditional Korean herbal medicines within 2
             weeks or any over-the-counter drugs or vitamin products within 1 week prior to the
             first dosing

          -  An individual who participated in another clinical trial and was administered any
             investigational product within 3 months prior to the first dosing.

          -  Whole blood donation within 2 months, apheresis donation within 1 month, or blood
             transfusion within 1 month prior to the first dosing.

          -  An individual who drinks excessive amounts of alcohol or who cannot stop drinking
             alcohol from 24 hours prior to hospital admission through to hospital discharge.

          -  Having smoked 10 cigarettes/day or more on average over the past 3 months.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical trials center of Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <state>Jung-gu</state>
        <zip>301-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>October 5, 2015</study_first_submitted>
  <study_first_submitted_qc>December 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2018</study_first_posted>
  <last_update_submitted>December 26, 2018</last_update_submitted>
  <last_update_submitted_qc>December 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Food Effect</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

